Dec 7 2010
China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. ("Shandong Taibang") and Guiyang Dalin Biologic Technologies Co., Ltd. ("Dalin"), and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that it has received a plasma collection license from the Shandong Province Health Department for its newly built plasma collection station in Yishui county, Shandong province and will commence commercial plasma collection on December 9, 2010.
The Company received approval to build two new plasma collection stations in Yishui and Ningyang counties in May 2010. Once the two new stations are operating, the Company will own seven of the eight plasma collection stations in Shandong province, and a total of 18 plasma collection stations nationwide, with up to 660 metric tons of plasma collection capacity when the two new plasma stations are at their optimal capacity.
"We are pleased to be commencing operations at the Yishui station," said Mr. Chao Ming Zhao, Chief Executive Officer of China Biologic. "With the additional plasma supply and the advancement of our product pipeline, we expect to continue increasing our market share in China."
Source:
China Biologic Products, Inc.